SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN

SteelPeak Wealth LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 28.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,728 shares of the medical research company’s stock after purchasing an additional 25,389 shares during the period. Amgen makes up 1.2% of SteelPeak Wealth LLC’s investment portfolio, making the stock its 20th biggest holding. SteelPeak Wealth LLC’s holdings in Amgen were worth $37,879,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Board of the Pension Protection Fund bought a new stake in shares of Amgen during the 4th quarter worth about $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen during the 4th quarter valued at about $33,000. Holos Integrated Wealth LLC bought a new position in shares of Amgen in the 4th quarter valued at approximately $37,000. Howard Hughes Medical Institute bought a new position in shares of Amgen in the 2nd quarter valued at approximately $32,000. Finally, Cloud Capital Management LLC acquired a new stake in Amgen in the 3rd quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN opened at $347.94 on Friday. The stock’s 50 day simple moving average is $363.65 and its 200-day simple moving average is $332.36. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a market cap of $187.56 billion, a PE ratio of 24.45, a P/E/G ratio of 3.45 and a beta of 0.47. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the business earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Truist Financial boosted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Barclays started coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. Guggenheim raised their target price on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.